PE19496A1 - Formulacion de analogo de insulina humana - Google Patents

Formulacion de analogo de insulina humana

Info

Publication number
PE19496A1
PE19496A1 PE1995271263A PE27126395A PE19496A1 PE 19496 A1 PE19496 A1 PE 19496A1 PE 1995271263 A PE1995271263 A PE 1995271263A PE 27126395 A PE27126395 A PE 27126395A PE 19496 A1 PE19496 A1 PE 19496A1
Authority
PE
Peru
Prior art keywords
human insulin
cresol
lys
pro
molecules
Prior art date
Application number
PE1995271263A
Other languages
English (en)
Inventor
Diane Lee Bakaysa
David Nettleship Brems
Allen Howard Pekar
Bruce Hill Frank
Henry Acken Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE19496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE19496A1 publication Critical patent/PE19496A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN HEXAMERO COMPLEJO DE INSULINA QUE COMPRENDE: a) SEIS MOLECULAS DE UN ANALOGO DE INSULINA HUMANA, b) DOS IONES ZINC, c) TRES MOLECULAS DE UN DERIVADO FENOLICO TAL COMO m-CRESOL, FENOL o UNA MEZCLA DE ELLOS, CARACTERIZADO PORQUE EL PORCENTAJE DE ABSORCION ES SIGNIFICATIVAMENTE MAS RAPIDA QUE LA INSULINA HUMANA REGULAR; SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA PARENTERAL QUE COMPRENDE EL COMPLEJO ANALOGO A LA INSULINA HUMANA-LYS B28 PRO B29, EL CUAL PUEDE CONTENER UN AGENTE DE ISOTONICIDAD TAL COMO GLICERINA, Y UN TAMPON FISIOLOGICAMENTE TOLERADO COMO FOSFATO SODICO; CONTIENE APROXIMADAMENTE: 3,5 mg/ml DE INSULINA HUMANA-LYS B28 PRO B29; 19,7 �g/ml DE ZINC, 7 mM de FOSFATO DE SODIO; 16 mg/ml DE GLICERINA Y 29 mM de m-CRESOL. ES UTIL EN EL TRATAMIENTO DE LA DIABETES MELLITUS
PE1995271263A 1994-06-16 1995-06-14 Formulacion de analogo de insulina humana PE19496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (1)

Publication Number Publication Date
PE19496A1 true PE19496A1 (es) 1996-06-01

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995271263A PE19496A1 (es) 1994-06-16 1995-06-14 Formulacion de analogo de insulina humana

Country Status (39)

Country Link
US (1) US5474978A (es)
JP (2) JP3171541B2 (es)
KR (1) KR100382326B1 (es)
CN (1) CN1105576C (es)
AT (1) AT408720B (es)
BE (1) BE1009408A5 (es)
BR (1) BR9502795A (es)
CA (1) CA2151560C (es)
CH (2) CH689250A5 (es)
CO (1) CO4410203A1 (es)
CZ (1) CZ287484B6 (es)
DE (1) DE19521720B4 (es)
DK (1) DK173015B1 (es)
ES (1) ES2091727B1 (es)
FI (1) FI118207B (es)
FR (2) FR2721214B1 (es)
GB (1) GB2291427B (es)
GR (1) GR1003004B (es)
HK (1) HK1015138A1 (es)
HU (1) HU227240B1 (es)
IE (1) IE68853B1 (es)
IL (1) IL114151A (es)
IT (1) IT1276723B1 (es)
LU (1) LU88626A1 (es)
MY (1) MY115631A (es)
NL (1) NL1000566C2 (es)
NO (1) NO322128B1 (es)
NZ (1) NZ272359A (es)
PE (1) PE19496A1 (es)
PL (1) PL181310B1 (es)
PT (1) PT101722B (es)
RO (1) RO113530B1 (es)
RS (1) RS49577B (es)
RU (1) RU2152399C2 (es)
SE (1) SE509052C2 (es)
SI (1) SI9500200A (es)
TW (1) TW421596B (es)
UA (1) UA26874C2 (es)
ZA (1) ZA954943B (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
WO1997048414A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S INSULIN PREPARATIONS CONTAINING NaCl
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
ES2228728T3 (es) * 1998-10-16 2005-04-16 Novo Nordisk A/S Preparaciones concentradas estables de insulina para administracion pulmonar.
DK1121145T3 (da) * 1998-10-16 2002-08-12 Novo Nordisk As Insulinpræparater til indgivelse via lungerne, som indeholder mentol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69914934T2 (de) * 1998-11-18 2005-01-05 Novo Nordisk A/S Stabile, wässrige insulin-präparate ohne phenol und cresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
MXPA05013723A (es) 2003-06-17 2006-03-13 Sembiosys Genetics Inc Metodos para loa produccion de insulina en plantas.
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
AU2005240213B8 (en) 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
AU2005249410A1 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
EP1750674A4 (en) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp MICROPARTICLES FOR THE ORAL LEVY
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2005291233B2 (en) * 2004-10-05 2011-02-03 Novo Nordisk A/S A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1862174A1 (en) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Inhibitor for insulin polymer formation
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
KR20080049128A (ko) 2005-09-19 2008-06-03 에미스페어 테크놀로지스, 인코포레이티드 Ｎ-(5-클로로살리실로일)-8-아미노카프릴산 이나트륨염의결정형
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009527526A (ja) * 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
CA2680737C (en) * 2007-03-21 2015-12-15 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
EP2514412A1 (en) * 2007-04-30 2012-10-24 Novo Nordisk A/S Highly Concentrated Insulin Solutions and Compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
EP2982687A1 (en) 2008-07-31 2016-02-10 Case Western Reserve University Halogen-stabilized insulin
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
US20110293562A1 (en) 2009-02-12 2011-12-01 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AU2011204425A1 (en) 2010-01-11 2012-08-02 Healor Ltd. Method for treatment of inflammatory disease and disorder
RU2576511C2 (ru) * 2010-02-24 2016-03-10 Эмисфире Текнолоджис, Инк. Пероральная терапия недостаточности витамина в12
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
JP6049087B2 (ja) 2010-09-30 2016-12-21 ソルヴェイ（ソシエテ アノニム） 天然起源のエピクロロヒドリンの誘導体
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012119007A1 (en) 2011-03-01 2012-09-07 N21 Acquisition Holding, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
US10159735B2 (en) * 2012-06-26 2018-12-25 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (en) 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6111475B2 (ja) 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
CN104870469A (zh) 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN109069532A (zh) 2016-02-11 2018-12-21 营养21有限责任公司 含铬组合物用于改善健康和健身
JP6920471B2 (ja) 2017-06-01 2021-08-18 イーライ リリー アンド カンパニー 迅速に作用するインスリン組成物
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
KR20220115927A (ko) 2019-10-25 2022-08-19 세르카코르 래버러토리즈, 인크. 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법
US20230134116A1 (en) 2020-03-31 2023-05-04 Protomer Technologies, Inc. Conjugates for selective responsiveness to vicinal diols
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
AU6995794A (en) * 1993-06-21 1995-01-17 Novo Nordisk A/S Aspb28 insulin crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
RU2152399C2 (ru) 2000-07-10
AU2168095A (en) 1996-01-04
FR2721214B1 (fr) 1997-09-26
GR950100229A (en) 1996-02-29
HK1015138A1 (en) 1999-10-08
RU95110109A (ru) 1997-05-10
DK173015B1 (da) 1999-11-15
DE19521720B4 (de) 2009-09-03
GB2291427B (en) 1998-09-16
FR2741078B1 (fr) 1998-08-07
IL114151A0 (en) 1995-10-31
FR2741078A1 (fr) 1997-05-16
FI118207B (fi) 2007-08-31
YU39695A (sh) 1997-08-22
NL1000566A1 (nl) 1995-12-18
NO952357L (no) 1995-12-18
DE19521720A1 (de) 1995-12-21
ES2091727A1 (es) 1996-11-01
NZ272359A (en) 1996-10-28
NO952357D0 (no) 1995-06-14
PL181310B1 (pl) 2001-07-31
IL114151A (en) 2000-09-28
FI952931A0 (fi) 1995-06-14
UA26874C2 (uk) 1999-12-29
KR960000924A (ko) 1996-01-25
CH689250A5 (de) 1999-01-15
AT408720B (de) 2002-02-25
RO113530B1 (ro) 1998-08-28
HUT73186A (en) 1996-06-28
IE68853B1 (en) 1996-07-24
ITMI951278A0 (it) 1995-06-14
MY115631A (en) 2003-08-30
HU9501716D0 (en) 1995-08-28
CO4410203A1 (es) 1997-01-09
SE9502167L (sv) 1995-12-17
FI952931A (fi) 1995-12-17
CZ287484B6 (en) 2000-12-13
PL309098A1 (en) 1995-12-27
PT101722A (pt) 1995-12-29
FR2721214A1 (fr) 1995-12-22
GR1003004B (el) 1998-11-05
CH689935A5 (de) 2000-02-15
GB9512038D0 (en) 1995-08-09
CA2151560C (en) 2000-05-09
DK67795A (da) 1995-12-17
CN1122248A (zh) 1996-05-15
US5474978A (en) 1995-12-12
ITMI951278A1 (it) 1996-12-14
BE1009408A5 (fr) 1997-03-04
JP2001199899A (ja) 2001-07-24
HU227240B1 (en) 2010-12-28
SE509052C2 (sv) 1998-11-30
PT101722B (pt) 1997-02-28
SE9502167D0 (sv) 1995-06-14
IE950436A1 (en) 1995-12-27
ATA101695A (de) 2001-07-15
AU694501B2 (en) 1998-07-23
BR9502795A (pt) 1996-03-12
TW421596B (en) 2001-02-11
LU88626A1 (fr) 1996-02-01
CA2151560A1 (en) 1995-12-17
ZA954943B (en) 1997-09-14
RS49577B (sr) 2007-04-10
IT1276723B1 (it) 1997-11-03
JPH083067A (ja) 1996-01-09
CN1105576C (zh) 2003-04-16
NL1000566C2 (nl) 1996-12-03
KR100382326B1 (ko) 2003-07-07
CZ154295A3 (en) 1996-02-14
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
JP3171541B2 (ja) 2001-05-28
SI9500200A (en) 1996-02-29
NO322128B1 (no) 2006-08-21

Similar Documents

Publication Publication Date Title
PE19496A1 (es) Formulacion de analogo de insulina humana
PE79099A1 (es) Formulaciones de insulina estables
BR9911656A (pt) Composição farmacêutica, processos para prevenção ou tratamento de diabetes em um mamìfero, para prevenção ou tratamento de complicações diabéticas em um mamìfero e para prevenção ou tratamento da tolerância a glicose prejudicada em um mamìfero, uso de um sensibilizador de insulina, e, proceso para reduzir os efeitos colaterais de um sensibilizador de insulina ou/ e um anorético administrado a um mamìfero diabético
BR0112356A (pt) Formulações farmacêuticas tópicas e métodos de tratamento
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
FI900052A (fi) Kompositioner och behandlingsmetoder foer hemorrojder och annat.
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
ES2180511T3 (es) Formulaciones monodispersas de analogos de insulina acilados hexamericos.
ES2150020T3 (es) Aumento de la concentracion de creatina y glucogeno en el musculo.
NO842290L (no) Fremgangsmaate for fremstilling av preparater inneholdende oralt antidiabetisk aktive stoffer
EP0103878A3 (en) Preparations for treating outer skin wounds and process for their manufacture
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
CA2326662A1 (en) Therapeutic system which can be moisture-activated
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ES2142388T3 (es) Agente anti-diabetico.
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term